Skip to content

Home Search Authors Pakistan News Saved

SciRah

SciRah does not host or store research papers. Results come live from free, official scholarly APIs, and every paper links back to its original source.

Data sources

OpenAlex
Semantic Scholar
Crossref
CORE
arXiv
PubMed

Privacy policy Terms of service

S. Sasse · SciRah

Researcher profile · Semantic Scholar

S. Sasse

Share profile

S. Sasse — researcher profile on SciRah

h-index: 27
Works: 70
Citations: 3,332

Most-cited papers

Human leukocyte antigen-B-associated transcript 3 is released from tumor cells and engages the NKp30 receptor on natural killer cells.
Elke Pogge von Strandmann, V. R. Simhadri, B. von Tresckow, S. Sasse +9 more
2007Immunity368 citations Open access
Semantic Scholar
Major Histocompatibility Complex Class II and Programmed Death Ligand 1 Expression Predict Outcome After Programmed Death 1 Blockade in Classic Hodgkin Lymphoma.
M. Roemer, R. Redd, F. Cader, Christine J. Pak +25 more
2018Journal of Clinical Oncology326 citations Open access
Semantic Scholar
A phase 1 study of the bispecific anti-CD30/CD16A antibody construct AFM13 in patients with relapsed or refractory Hodgkin lymphoma.
A. Rothe, S. Sasse, M. Topp, D. Eichenauer +12 more
2011Blood309 citations Open access
Semantic Scholar
Positron Emission Tomography-Guided Treatment in Early-Stage Favorable Hodgkin Lymphoma: Final Results of the International, Randomized Phase III HD16 Trial by the German Hodgkin Study Group.
M. Fuchs, H. Goergen, C. Kobe, G. Kuhnert +25 more
2019Journal of Clinical Oncology188 citations Open access
Semantic Scholar
Omission of dacarbazine or bleomycin, or both, from the ABVD regimen in treatment of early-stage favourable Hodgkin's lymphoma (GHSG HD13): an open-label, randomised, non-inferiority trial.
K. Behringer, H. Goergen, F. Hitz, J. Zijlstra +32 more
2015The Lancet167 citations
Semantic Scholar
Efficacy of Nivolumab and AVD in Early-Stage Unfavorable Classic Hodgkin Lymphoma: The Randomized Phase 2 German Hodgkin Study Group NIVAHL Trial.
P. Bröckelmann, H. Goergen, U. Keller, J. Meissner +18 more
2020JAMA Oncology164 citations Open access
Semantic Scholar
High-dose methotrexate-based immuno-chemotherapy for elderly primary CNS lymphoma patients (PRIMAIN study)
K. Fritsch, B. Kasenda, E. Schorb, P. Hau +24 more
2016Leukemia158 citations Open access
Semantic Scholar
Therapy-related acute myeloid leukemia and myelodysplastic syndromes in patients with Hodgkin lymphoma: a report from the German Hodgkin Study Group.
D. Eichenauer, Indra Thielen, H. Haverkamp, J. Franklin +11 more
2014Blood134 citations Open access
Semantic Scholar
Long-Term Follow-Up of Contemporary Treatment in Early-Stage Hodgkin Lymphoma: Updated Analyses of the German Hodgkin Study Group HD7, HD8, HD10, and HD11 Trials.
S. Sasse, P. Bröckelmann, H. Goergen, A. Plütschow +8 more
2017Journal of Clinical Oncology128 citations
Semantic Scholar
The emerging role of immune checkpoint inhibition in malignant lymphoma
I. Hude, S. Sasse, A. Engert, P. Bröckelmann
2017Haematologica111 citations Open access
Semantic Scholar
Brentuximab vedotin for relapsed or refractory CD30+ hematologic malignancies: the German Hodgkin Study Group experience.
A. Rothe, S. Sasse, H. Goergen, D. Eichenauer +8 more
2012Blood95 citations
Semantic Scholar
Human angiogenin fused to human CD30 ligand (Ang-CD30L) exhibits specific cytotoxicity against CD30-positive lymphoma.
M. Huhn, S. Sasse, M. Tur, B. Matthey +4 more
2001Cancer Research81 citations
Semantic Scholar
Tumor and microenvironment response but no cytotoxic T-cell activation in classic Hodgkin lymphoma treated with anti-PD1.
S. Reinke, P. Bröckelmann, I. Iaccarino, M. García-Márquez +22 more
2020Blood69 citations Open access
Semantic Scholar
Treatment-related mortality in patients with advanced-stage hodgkin lymphoma: an analysis of the german hodgkin study group.
Diana Wongso, M. Fuchs, A. Plütschow, B. Klimm +10 more
2013Journal of Clinical Oncology67 citations Open access
Semantic Scholar
In-depth cell-free DNA sequencing reveals genomic landscape of Hodgkin's lymphoma and facilitates ultrasensitive residual disease detection.
Sophia Sobesky, L. Mammadova, M. Cirillo, E. Drees +22 more
2021i Medicina62 citations Open access
Semantic Scholar
Long-Term Follow-Up of Patients With Nodular Lymphocyte-Predominant Hodgkin Lymphoma Treated in the HD7 to HD15 Trials: A Report From the German Hodgkin Study Group.
D. Eichenauer, A. Plütschow, M. Fuchs, S. Sasse +6 more
2020Journal of Clinical Oncology62 citations
Semantic Scholar
Relapsed hodgkin lymphoma in older patients: a comprehensive analysis from the German hodgkin study group.
B. Böll, H. Goergen, Nils Arndt, J. Meissner +12 more
2013Journal of Clinical Oncology62 citations Open access
Semantic Scholar
Hodgkin Lymphoma—Review on Pathogenesis, Diagnosis, Current and Future Treatment Approaches for Adult Patients
J. Momotow, S. Borchmann, D. Eichenauer, A. Engert +1 more
2021Journal of Clinical Medicine61 citations Open access
Semantic Scholar
AFM13 in patients with relapsed or refractory classical Hodgkin lymphoma: final results of an open-label, randomized, multicenter phase II trial
S. Sasse, P. Bröckelmann, J. Momotow, A. Plütschow +14 more
2022Leukemia and Lymphoma57 citations
Semantic Scholar
Brentuximab vedotin (SGN-35) in patients with transplant-naive relapsed/refractory Hodgkin lymphoma
S. Sasse, A. Rothe, H. Goergen, D. Eichenauer +8 more
2013Leukemia and Lymphoma53 citations
Semantic Scholar
Intensive treatment strategies in advanced-stage Hodgkin's lymphoma (HD9 and HD12): analysis of long-term survival in two randomised trials.
B. von Tresckow, S. Kreissl, H. Goergen, P. Bröckelmann +11 more
2018The Lancet Haematology48 citations Open access
Semantic Scholar
Early Response to First-Line Anti–PD-1 Treatment in Hodgkin Lymphoma: A PET-Based Analysis from the Prospective, Randomized Phase II NIVAHL Trial
C. Voltin, J. Mettler, L. van Heek, H. Goergen +14 more
2020Clinical Cancer Research40 citations Open access
Semantic Scholar
Comparing long-term toxicity and efficacy of combined modality treatment including extended- or involved-field radiotherapy in early-stage Hodgkin's lymphoma.
S. Sasse, B. Klimm, H. Görgen, M. Fuchs +11 more
2012Annals of Oncology40 citations Open access
Semantic Scholar
Balancing risk and benefit in early-stage classical Hodgkin lymphoma.
P. Bröckelmann, S. Sasse, A. Engert
2018Blood39 citations
Semantic Scholar
Selection of scFv phages on intact cells under low pH conditions leads to a significant loss of insert-free phages.
M. Tur, M. Huhn, S. Sasse, A. Engert +1 more
2001BioTechniques39 citations Open access
Semantic Scholar
Outcome and risk factors of patients with Hodgkin Lymphoma who relapse or progress after autologous stem cell transplant
B. von Tresckow, H. Müller, D. Eichenauer, J. Glossmann +7 more
2014Leukemia and Lymphoma33 citations
Semantic Scholar
Leucocyte and eosinophil counts predict progression‐free survival in relapsed or refractory classical Hodgkin Lymphoma patients treated with PD1 inhibition
I. Hude, S. Sasse, P. Bröckelmann, B. von Tresckow +3 more
2018British Journal of Haematology31 citations Open access
Semantic Scholar
Pretreatment Vitamin D Deficiency Is Associated With Impaired Progression-Free and Overall Survival in Hodgkin Lymphoma.
S. Borchmann, M. Cirillo, H. Goergen, L. Meder +7 more
2019Journal of Clinical Oncology27 citations
Semantic Scholar
An anti-GD2 single chain Fv selected by phage display and fused to Pseudomonas exotoxin A develops specific cytotoxic activity against neuroblastoma derived cell lines.
M. Tur, S. Sasse, M. Stöcker, K. Djabelkhir +6 more
2001International Journal of Molecular Medicine27 citations
Semantic Scholar
Construction of phage display libraries from reactive lymph nodes of breast carcinoma patients and selection for specifically binding human single chain Fv on cell lines.
A. Rothe, Alexander Klimka, M. Tur, T. Pfitzner +5 more
2004International Journal of Molecular Medicine26 citations
Semantic Scholar
Reverted exhaustion phenotype of circulating lymphocytes as immune correlate of anti-PD1 first-line treatment in Hodgkin lymphoma
M. García-Márquez, M. Thelen, S. Reinke, D. Keller +13 more
2021Leukemia25 citations Open access
Semantic Scholar
18-Fluorodeoxyglucose positron emission tomography/computed tomography for assessment of response to brentuximab vedotin treatment in relapsed and refractory Hodgkin lymphoma
D. Kahraman, S. Theurich, A. Rothe, G. Kuhnert +6 more
2014Leukemia and Lymphoma21 citations
Semantic Scholar
9p24.1 alterations and programmed cell death 1 ligand 1 expression in early stage unfavourable classical Hodgkin lymphoma: an analysis from the German Hodgkin Study Group NIVAHL trial
E. Gerhard-Hartmann, H. Goergen, P. Bröckelmann, A. Mottok +14 more
2021British Journal of Haematology20 citations Open access
Semantic Scholar
Programmed cell death protein-1 (PD-1)-expression in the microenvironment of classical Hodgkin lymphoma at relapse during anti-PD-1-treatment
S. Sasse, K. Reddemann, A. Diepstra, I. Oschlies +5 more
2018Haematologica19 citations Open access
Semantic Scholar
Simvastatin-dependent apoptosis in Hodgkin's lymphoma cells and growth impairment of human Hodgkin's tumors in vivo.
B. von Tresckow, E. P. von Strandmann, S. Sasse, S. Tawadros +2 more
2007Haematologica19 citations Open access
Semantic Scholar
PET-Guided Treatment of Early-Stage Favorable Hodgkin Lymphoma: Final Results of the International, Randomized Phase 3 Trial HD16 By the German Hodgkin Study Group
M. Fuchs, H. Goergen, C. Kobe, H. Eich +12 more
2018Blood18 citations
Semantic Scholar
Impact of Bleomycin and Vincristine Dose Reductions in Patients With Advanced Hodgkin Lymphoma Treated With BEACOPP: An Analysis of the German Hodgkin Study Group HD12 and HD15 Trials.
H. Haverkamp, B. Böll, D. Eichenauer, S. Sasse +5 more
2015Journal of Clinical Oncology16 citations Open access
Semantic Scholar
Prognostic relevance of DHAP dose-density in relapsed Hodgkin lymphoma: an analysis of the German Hodgkin-Study Group
S. Sasse, Magdalena Alram, H. Müller, L. Smardova +11 more
2016Leukemia and Lymphoma13 citations
Semantic Scholar
Brentuximab Vedotin (SGN-35) in Patients with Relapsed/Refractory CD30-Positive Hematologic Malignancies without Prior High-Dose Chemotherapy and Stem Cell Transplantation.
A. Rothe, S. Sasse, H. Goergen, D. Eichenauer +4 more
201213 citations
Semantic Scholar
Nivolumab and AVD for Early-Stage Unfavorable Hodgkin Lymphoma (NIVAHL)
P. Bröckelmann, H. Goergen, U. Keller, J. Meissner +17 more
2019Blood11 citations Open access
Semantic Scholar
Bendamustine followed by ofatumumab and ibrutinib in chronic lymphocytic leukemia: primary endpoint analysis of a multicenter, open-label, phase II trial (CLL2-BIO)
P. Cramer, J. von Tresckow, S. Robrecht, J. Bahlo +20 more
2020Haematologica10 citations Open access
Semantic Scholar
Outcome of Patients With Early-Stage Infradiaphragmatic Hodgkin Lymphoma: A Comprehensive Analysis From the German Hodgkin Study Group.
S. Sasse, H. Goergen, A. Plütschow, B. Böll +13 more
2018Journal of Clinical Oncology9 citations Open access
Semantic Scholar
Venetoclax plus rituximab or obinutuzumab after allogeneic hematopoietic stem cell transplantation in chronic lymphocytic leukemia
O. Al-Sawaf, C. Herling, U. Holtick, C. Scheid +8 more
2019Haematologica7 citations Open access
Semantic Scholar
AFM13 in Patients with Relapsed or Refractory Hodgkin Lymphoma: Final Results of an Open-Label, Randomized, Multicenter Phase II Trial
S. Sasse, J. Momotow, A. Plütschow, A. Huettmann +13 more
2020Blood6 citations Open access
Semantic Scholar
Nivolumab in Relapsed/Refractory Classical Hodgkin Lymphoma – Extended Follow-up of 30 Patients Treated Within the CheckMate 205 Trial in a Single-Center
J. Momotow, H. Goergen, K. Behringer, P. Bröckelmann +5 more
2019HemaSphere6 citations Open access
Semantic Scholar
The in vitro anti-inflammatory effects of recombinant anti-CD25 immunotoxin on lamina propria T cells of patients with inflammatory bowel disease are not sufficient to cure experimental colitis in mice
K. Pfister, B. Wittig, B. Jungling, K. Ecker +8 more
2002International Journal of Colorectal Disease6 citations
Semantic Scholar
Exhaustive circulating tumor DNA sequencing reveals the genomic landscape of Hodgkin lymphoma and facilitates ultrasensitive detection of minimal residual disease
Sophia Sobesky, L. Mammadova, M. Cirillo, E. Drees +22 more
2021medRxiv5 citations Open access
Semantic Scholar
Impact Of Dose Reduction Of Bleomycin and Vincristine In Patients With Advanced Hodgkin Lymphoma Treated With Beacopp: A Comprehensive Analysis Of The German Hodgkin Study Group (GHSG) HD12 and HD15 Trials
H. Haverkamp, B. Böll, D. Eichenauer, S. Sasse +3 more
20135 citations
Semantic Scholar
PET-Guided Treatment of Early-Stage Favorable Hodgkin Lymphoma: Final Results of the International, Randomized Phase 3 Trial HD16 by the GHSG
H. Eich, C. Baues, M. Fuchs, C. Kobe +11 more
2019International Journal of Radiation Oncology, Biology, Physics4 citations
Semantic Scholar
Programmed cell death protein1 (PD1)-expression in the microenvironment of classical Hodgkin lymphoma at relapse after conventional chemotherapy and at relapse on anti-PD1 treatment
S. Sasse, K. Reddemann, A. Diepstra, S. Borchmann +5 more
2018Haematologica4 citations Open access
Semantic Scholar

Frequent co-authors

Invite them to SciRah by sharing their profile.

A. Engert×40
Invite
A. Engert — researcher profile on SciRah
P. Borchmann×30
Invite
P. Borchmann — researcher profile on SciRah
B. von Tresckow×24
Invite
B. von Tresckow — researcher profile on SciRah
M. Fuchs×22
Invite
M. Fuchs — researcher profile on SciRah

×16

Invite

H. Goergen — researcher profile on SciRah

P. Bröckelmann×16

Invite

P. Bröckelmann — researcher profile on SciRah

D. Eichenauer×12

Invite

D. Eichenauer — researcher profile on SciRah

S. Borchmann×12

Invite

S. Borchmann — researcher profile on SciRah

Invite

B. Böll — researcher profile on SciRah

Invite

C. Kobe — researcher profile on SciRah

Invite

V. Diehl — researcher profile on SciRah

Invite

C. Baues — researcher profile on SciRah